GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Gossamer Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.43−0.34 (-3.88%)
Close on Oct 19, 2026
- Market cap
- $2.77B
- P/E (TTM)
- –
- Dividend yield
- –
Gossamer Bio, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from contracts with collaborators | $9.24M | $16.96M | $13.80M | $13.29M | $11.49M | $9.89M | $7.45M | $9.48M | $7.09M | $0 | $0 | $0 | 100.0% | -19.6% |
| Revenue from sale of licenses | – | – | $0 | $0 | $0 | – | $1.93M | $0 | $88.75M | – | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Gossamer Bio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.